Bass targets Juxtapid in IPR challenge

Kyle Bass' Coalition for Affordable Drugs VIII filed two new inter partes review (IPR) petitions with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office challenging two patents from the University of Pennsylvania that cover Juxtapid lomitapide from Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR).

The petitions challenge U.S. Patents Nos. 8,618,135 and 7,932,268, which Aegerion has licensed. Both patents cover dosing methods to treat hyperlipidemia and hypercholesterolemia. The '135 patent expires in 2025 and the '268 patent in 2027. ...